Want to see ANNX full AI Analyst Report?
ANNX Stock Chart & Stats
$5.15
$0.06(1.15%)
At close: 4:00 PM EDT
$5.15
$0.06(1.15%)
Day’s Range― - ―
52-Week Range$2.32 - $7.18
Previous CloseN/A
Volume142.64K
Average Volume (3M)2.44M
Market Cap
$784.86M
Enterprise Value$963.14
Total Cash (Recent Filing)$209.24M
Total Debt (Recent Filing)$24.65M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Nov 16, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.16
Shares Outstanding189,579,130
10 Day Avg. Volume2,160,301
30 Day Avg. Volume2,438,331
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)3.68
Price to Sales (P/S)0.00
P/FCF Ratio-4.18
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.00Price Target Upside171.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.05
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
GBS Clinical And Regulatory ProgressRapid and reproducible tanruprubart responses, together with an ongoing EMA review and planned U.S. filing, support a credible path toward commercialization. If confirmed by regulators, the program could address substantial unmet need and establish an important position in GBS therapy.
Strong ARCHER II Trial ExecutionEnrollment above target, high dosing compliance and low discontinuation reduce operational execution risk and improve the quality of the eventual dataset. These characteristics support confidence that ARCHER II can generate interpretable evidence for vonaprument's potential in geographic atrophy.
Extended Funding RunwayA substantial cash balance combined with committed financing gives Annexon more time to advance late-stage programs through important clinical and regulatory milestones. The extended runway may reduce near-term dependence on equity issuance while preserving resources for pipeline development.
Bears Say
No Commercial Revenue And Worsening LossesThe absence of product revenue leaves Annexon dependent on financing and future approvals to create operating income. Rising losses indicate that development costs are increasing faster than any emerging monetization, limiting operating leverage and making future profitability highly conditional.
Persistent Cash BurnHeavy negative operating and free cash flow means the company is consuming capital rather than funding operations internally. Continued burn can shorten the effective runway, increase dependence on external financing and constrain investment choices if clinical timelines or spending requirements expand.
Trial And Endpoint UncertaintyThe dual-primary design adds statistical complexity and creates uncertainty over which endpoint will deliver the decisive result. DMC decisions could also delay the final readout or stop development, making the timing and strength of evidence for geographic atrophy less predictable.
Annexon Biosciences News
ANNX FAQ
What was Annexon Biosciences’s price range in the past 12 months?
Annexon Biosciences lowest stock price was $2.32 and its highest was $7.18 in the past 12 months.
What is Annexon Biosciences’s market cap?
Annexon Biosciences’s market cap is $784.86M.
When is Annexon Biosciences’s upcoming earnings report date?
Annexon Biosciences’s upcoming earnings report date is Nov 16, 2026 which is in 65 days.
How were Annexon Biosciences’s earnings last quarter?
Annexon Biosciences released its earnings results on Aug 12, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.239 by -$0.041.
Is Annexon Biosciences overvalued?
According to Wall Street analysts Annexon Biosciences’s price is currently Undervalued.
Does Annexon Biosciences pay dividends?
Annexon Biosciences does not currently pay dividends.
What is Annexon Biosciences’s EPS estimate?
Annexon Biosciences’s EPS estimate is -0.28.
How many shares outstanding does Annexon Biosciences have?
Annexon Biosciences has 189,579,130 shares outstanding.
What happened to Annexon Biosciences’s price movement after its last earnings report?
Annexon Biosciences reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.239. Following the earnings report the stock price went down -0.187%.
Which hedge fund is a major shareholder of Annexon Biosciences?
Currently, no hedge funds are holding shares in ANNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Annexon Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.00 (171.84% Upside)
$14.00 (171.84% Upside)
Blogger Sentiment
Bullish
ANNX Sentiment 100%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Increased
By 5.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
54.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.99%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Annexon Biosciences
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.
ANNX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and operational momentum: first-in-class pivotal GBS data with regulatory filings progressing, robust ARCHER II execution (659 enrolled, >95% dosing compliance, <10% discontinuation) and a strategic expansion to a month 24 dual primary endpoint that management says is well powered (>90%). Financial flexibility was improved with up to $200M in non-dilutive capital. Primary risks noted include the requirement to split alpha between month 15 and month 24 (undisclosed allocation), potential DMC-driven continuation or futility decisions that could delay readouts, and the introduction of debt obligations. Overall, the highlights — compelling clinical results, regulatory progress, strong trial execution and extended runway — materially outweigh the risks presented.View all ANNX earnings summariesANNX Stock 12 Month Forecast
Average Price Target
$14.00
▲(171.84% Upside)
Technical Analysis
Galectin Therapeutics
―
Aldeyra Therapeutics
―
Editas Medicine
―
Alector
―
Neumora Therapeutics, Inc.
―
Ownership Overview
6.14% Insiders
16.18% Mutual Funds
39.69% Other Institutional Investors
23.30% Public Companies and
Individual Investors